Skip to main content

Acasti Pharma(ACST-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low1.7200
Day High1.9800
Open:1.9500
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Reports for Acasti Pharma

News for Acasti Pharma

Select a category then submit the form to load news
PR Newswire
Acasti Pharma Announces 1-for-6 Reverse Stock Split
PR Newswire
Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023
PR Newswire
Acasti Pharma Reports Fiscal Year 2023 Operational Results
Baystreet
Short Week in U.S.
PR Newswire
Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025
PR Newswire
Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND
PR Newswire
Acasti Pharma Inc. Announces the Resignation of a Director
PR Newswire
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange
PR Newswire
Acasti Pharma Recognizes Rare Disease Day
Globe Newswire
Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022
Globe Newswire
Acasti Pharma Announces Annual Grants of Performance Stock Options
Globe Newswire
Acasti Pharma Reports Fiscal Year 2022 Operational Results
Globe Newswire
Acasti Pharma Schedules Fiscal Year 2022 Business Update Conference Call
Globe Newswire
Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints
AccessWire
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022
AccessWire
Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th
Globe Newswire
Acasti Pharma to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28th
Globe Newswire
Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors
Globe Newswire
Acasti Pharma Announces Patents for GTX-104 in Europe, GTX-102 in the U.S. and GTX-101 in Japan
Globe Newswire
Acasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16th
Globe Newswire
Acasti Pharma Celebrates Rare Disease Day
Globe Newswire
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022
Globe Newswire
Acasti Pharma Schedules Third Quarter Fiscal 2022 Business Update Conference Call
Globe Newswire
Acasti Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference
Globe Newswire
Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104
Globe Newswire
Acasti Pharma CEO to Participate in the Benzinga All Access Event on December 2nd
Investor Brand Network
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies
Globe Newswire
Acasti Pharma Announces Annual Stock Option Grants
Globe Newswire
Acasti Pharma Schedules Second Quarter Fiscal 2022 Business Update Conference Call
Globe NewsWire
Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage
Globe NewsWire
Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards
Globe NewsWire
Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21ˢᵗ
More Acasti Pharma news

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.